About US
Contact us
-
Bayer business up in the air as COVID-19 and Roundup litigation uncertainties persistLike several other pharma companies, Bayer enjoyed a better-than-expected first quarter in the early days of COVID-19. But the German conglomerate finds the uncertainties spawned by the pandemic make2020/4/27
-
After disappointing early numbers, Sanofi and Regeneron scale back Kevzara's COVID-19 testSanofi and Regeneron had high hopes for IL-6 inhibitor Kevzara's chances as a repurposed therapy for COVID-19 patients after anecdotal results in China showed promise. But now, the drug has hit an ea2020/4/27
-
J&J, AbbVie's Imbruvica pads CLL lead with FDA green light in younger patientsMany chronic lymphocytic leukemia (CLL) patients start out on Johnson & Johnson and AbbVie’s Imbruvica, a blockbuster that until recently had five indications in the disease. Thanks to a sixthgra2020/4/23
-
Early treatment with Novartis' Mayzent stalls secondary progressive MS: studyNovartis is looking to grow its new multiple sclerosis drug Mayzent in a crowded field, and, with Gilenya generics threatening, the newer MS medicine may need to carry even more weight. It just racke2020/4/22
-
Bristol Myers, Exelixis scored a kidney cancer combo win. But is there room for their duo on the market?Bristol Myers Squibb and Exelixis have a potential kidney cancer contender on their hands—but they’ll have to meet a “high bar” to gain traction in the crowded field, one analyst says. A combination2020/4/21
-
Eyeing COVID-19 shortages, FDA unleashes compounded drugs to treat hospital patientsAfter a series of high-profilefailures in the early 2010s, the compounding pharmacy industry took its share ofbody blows from an FDA looking to impose its will. Now, after years of lockdown, the FDA2020/4/20
-
Alexion, following clues from early tests, preps phase 3 study of Ultomiris in severe COVID-19For about two months, Alexion has been exploring whether itsSoliris—used to treat several rare diseases—might holdpromise in treating patients with severeCOVID-19, the illness caused by the novel cor2020/4/20
-
FiercePharmaPolitics—With 'LIBERATE' tweets, Trump seems to endorse lockdown protestsWelcome to theFiercePharmapolitical roundup, where each Monday we’ll highlight political developments that could affect the pharmaceutical industry. As theU.S.economic toll from COVID-19 lockdowns co2020/4/17
-
Seattle Genetics breaks into breast cancer with new approval TukysaSeattle Genetics is officially ready to make its first foray into the breast cancer field, thanks to some "stunning" data and a brand-new FDA approval that came four months ahead of schedule. The age2020/4/16
-
Genentech, Novo Nordisk and AbbVie top the list of best workplaces in biopharmaBiopharma companies all vow to help patients, but how do they fare in creating healthy workplace environments for their employees? Roche’s Genentech, Novo Nordisk and AbbVie ranked as the top 3 onFor2020/4/15